BSPED2013

13 November 2013

09:30-18:30Registration
16:45-18:15Industry Sponsored Satellite Symposium - Updates on Turner Syndrome and Prader-Willi Syndrome
Chair(s):M Donaldson (Glasgow) & E Gevers (London)
Supported by Pfizer Limited
16:45Turner syndrome: what can we do better?
JC Carel (Paris, France)
17:30Prader-Willi Syndrome: update on MDT management of children with Prader-Wili Syndrome
A Hokken-Koelega (Rotterdam, The Netherlands)
18:15-19:00Welcome Reception

14 November 2013

08:00-18:00Registration
08:30-09:00Welcome and Lighting of the Lamp
J Cohen (Brighton)
09:00-10:30Oral Communications 1
Chair(s):D Ismail (Brighton) & J Barton (Bristol)
09:00OC1.1Growth Hormone (GH) testing – Reducing the need for a second test for the diagnosis of Growth Hormone deficiency
Z Juma (Birmingham)
09:10OC1.2A single centre audit of the 2012 UK Newborn Screening Programme Guidelines for pre-term infants
G Woods (Cardiff)
09:20OC1.3The Utility Of AMH For Predicting Testosterone Response To HCG Stimulation In Children With Suspected DSD
A Kyriakou (Glasgow, UK)
09:30OC1.4Abnormal glucose homeostasis in survivors of Childhood Acute Lymphoblastic Leukaemia (ALL) treated with Bone Marrow Transplantation (BMT) and Total Body Irradiation (TBI) is associated with reduced Beta-cell reserve and pancreatic volume
C Wei (Bristol, UK)
09:40OC1.5Novel Genes Affecting the Timing of Puberty
S Howard ()
09:50OC1.6Oral bisphosphonates as prophylaxis of steroid-induced osteoporosis in Duchenne Muscular Dystrophy
R Srinivasan (Newcastle Upon Tyne)
10:00OC1.7A mutation in thioredoxin reductase 2 (TXNRD2) is associated with familial glucocorticoid deficiency (FGD)
R Prasad (London)
10:10OC1.8The repressor activity of the Wnt/β-Catenin effector Tcf3/TCF7L1 is required for normal hypothalamic-pituitary development
C Gaston-Massuet ()
10:20OC1.9Genetic characterisation of short children with potential defects of GH action by single gene sequencing
J Kowalczyk (London)
10:30-11:00Tea & Coffee
11:00-12:30Symposium 1 – care and controversies: present and future
Chair(s):H Spoudeas (London) & H Gleeson (Leicester)
11:00S1.1Gonadal Function and Fertility after Cancer Treatment in Childhood
A Leiper (London)
11:30S1.2Preservation of fertility
R Anderson (Edinburgh)
12:00S1.3SAGhe: GH safety and long term concerns
JC Carel (Paris, France)
12:30-14:00Lunch
13:15-14:00Poster Tour
14:00-15:00Oral Communications 2
Chair(s):S Kanumakala (Brighton) & N Davis (Southampton)
14:00OC2.1Whole Exome Sequencing as a diagnostic tool in adrenal insufficiency
L Chan (London)
14:06OC2.2Increased bone area without reduction in volumetric bone mineral density in children treated with glucocorticoids for nephrotic syndrome
R Moon (Southampton, UK)
14:12OC2.3Clinical phenotype of patients with MCM4 mutation suggests pubertal delay in males
C Hughes (London)
14:18OC2.4FGF21 causes GH resistance in human chondrocytes through activation of SOCS2 and inhibition of IGF1 expression
L Guasti (London)
14:24OC2.5Continuous Subcutaneous Infusion of Parathyroid Hormone reduces PTH requirement in patient with activating mutation of the calcium sensing receptor
M Cheung ()
14:30OC2.6Review of the clinical scoring systems in Silver-Russell syndrome and development of modified diagnostic criteria to guide molecular genetic testing
R Dias ()
14:36OC2.7Novel lethal form of hypopituitarism associated with the first recessive LHX4 mutation
L Gregory ()
14:42OC2.8Establishing a national audit of paediatric GH prescribing
S Shepherd (Glasgow)
14:48OC2.9A comprehensive next generation sequencing-based strategy for genetic diagnosis in congenital hypothyroidism (CH)
N Schoenmakers (Cambridge)
14:54OC2.10A new approach to the definition and diagnosis of adrenal insufficiency during inhaled corticosteroid therapy for asthma
J Blair (Liverpool)
15:00-15:30Tea & Coffee
15:30-16:30Symposium 2 - Recent advances in CAH management
Chair(s):N Krone (Birmingham) & F Ahmed (Glasgow)
15:30S2.1CaHASE – A UK collaborative study on CAH in adults
R Ross (Sheffield)
16:00S2.2Paediatric surveillance for CAH – informing newborn screening policy
R Knowles (London)
16:45-18:00BSPED Annual General Meeting
19:00-19:30Pre-Dinner Welcome Reception
19:30-23:59Conference Dinner

15 November 2013

08:00-15:30Registration
08:00-08:50Industry Sponsored Satellite Symposium - Optimising endocrine care in the Hypopituitary Patient
Chair(s):M Dattani (London)
Supported by Sandoz Biopharmaceuticals
08:00Welcome and introductions
08:05Thyroxine and Hydrocortisone Replacement
S Shalet (Manchester)
08:25Growing up with Growth Hormone Deficiency – indicators and measures of successful endocrine care
H Gleeson ()
08:45Questions to the panel
09:00-10:30Symposium 3 - Present and future: novelty and goals
Chair(s):R Williams (Cambridge) & C Agwu (Birmingham)
09:00S3.1Benefits of diabetes networks and beyond
F Campbell (Leeds, UK)
09:30S3.2Complications of Type 1 Diabetes - Current dilemmas
R Amin (London)
10:00S3.3What are the barriers of implementation to BPT
T Randell (Nottingham)
10:30-11:00Tea & Coffee
11:00-11:30BSPED 2011 Research Award Winners Presentation
Chair(s):R Amin (London)
11:00Does SOX2 regulate bone stem / progenitor cells?
E Gevers (London)
11:10Understanding the role of Vitamin D in skeletal muscle function using
A Sinha (Newcastle Upon Tyne)
11:20Interplay of the fetal adrenal cortex, placental corticotrophin-releasing hormone
H Storr (UK)
11:30-12:30Oral Communications 3
Chair(s):R Kapoor (London) & J Greening (Leicester)
11:30OC3.1Catch up growth and insulin sensitivity in adolescent children born preterm
C Wood (Newcastle Upon Tyne)
11:40OC3.2GAD and IA2 autoantibody positivity is associated with a requirement for insulin treatment: results of the UK national paediatric Type 2 Diabetes cohort
T Barrett (Birmingham)
11:50OC3.3Successful Treatment of Four Patients with Severe Hyperinsulinaemic Hypoglycaemia with a novel therapy using mTOR Inhibitor
S Senniappan (London)
12:00OC3.4Successful Use of Long Acting Octreotide in Treatment of Congenital Hyperinsulinism
P Shah (London)
12:10OC3.5Loss of the tumour suppressor micro-RNA 34a, and anti tumour cellular immunity in paediatric obesity – is obesity increasing the future risk of cancer in children?
E Carolan (Dublin, Ireland)
12:20OC3.6A feasibility study of intra-gastric balloons (supported by a lifestyle programme) for the treatment of severe adolescent obesity - the (BOB) Study
P Sachdev ()
12:30-13:06Oral Communications 4
Chair(s):R Kapoor (London) & J Greening (Leicester)
12:30OC4.1Risk factors for emergency hospital admission for diabetic ketoacidosis in children and young people: national cross-sectional analysis
S Khare (London)
12:36OC4.2Maturity-onset diabetes of Young 5 (MODY5) with Gallbladder duplication cyst: a novel case
A Subbarayan (London)
12:42OC4.3The Incentive Trial: Do financial rewards improve glycaemic control in teenagers with poorly controlled Type 1 Diabetes?
C Frerichs ()
12:48OC4.4Special Features of Neonatal Diabetes in a Series of Arab Patients from the Gulf Region
A Deeb (Abu Dhabi, UAE)
12:54OC4.5Peer Review: A tool to improve Paediatric Diabetes services
JC Agwu (West Midlands)
13:00OC4.6Increased urinary Megalin and Cubulin excretion in children with Type 1 Diabetes Mellitus (T1DM) - an association with low molecular weight protein loss
E Sirka (London)
13:06-14:00Lunch
14:00-14:45Plenary Guest Lecture
Chair(s):P Hindmarsh (London)
14:00 -14:45 PL1Early intervention on type 1 diabetes
J Ludvigsson (Linköping, Sweden)
14:45-15:45Symposium 4 - Debate: Pump Vs MDI in all children with T1DM
Chair(s):T Cheetham (Newcastle) & J Blair (Liverpool)
14:45S4.1Pump therapy in all newly diagnosed T1DM
F Campbell (Leeds, UK)
15:15S4.2MDI in all newly diagnosed T1DM
T Hulse (London)
15:45-16:00Close of meeting